Prediction of Nodal Metastasis in Head and Neck Cancer Using a 3T MRI ADC Map

References

1. 1.↵
   1. Johnson JT

   . A surgeon looks at cervical lymph nodes. Radiology 1990;175:607–10

   PubMedWeb of Science
2. 2.↵
   1. Yousem DM,
   2. Som PM,
   3. Hackney DB,
   4. et al

   . Central nodal necrosis and extracapsular neoplastic spread in cervical lymph nodes: MR imaging versus CT. Radiology 1992;182:753–59

   PubMedWeb of Science
3. 3.↵
   1. van den Brekel MW,
   2. Castelijns JA,
   3. Snow GB

   . Detection of lymph node metastases in the neck: radiologic criteria. Radiology 1994;192:617–18

   PubMed
4. 4.↵
   1. Sumi M,
   2. Sakihama N,
   3. Sumi T,
   4. et al

   . Discrimination of metastatic cervical lymph nodes with diffusion-weighted MR imaging in patients with head and neck cancer. AJNR Am J Neuroradiol 2003;24:1627–34

   Abstract/FREE Full Text
5. 5.↵
   1. Vandecaveye V,
   2. De Keyzer F,
   3. Vander Poorten V,
   4. et al

   . Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology 2009;251:134–46

   CrossRefPubMed
6. 6.↵
   1. Abdel Razek AA,
   2. Soliman NY,
   3. Elkhamary S,
   4. et al

   . Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 2006;16:1468–77

   CrossRefPubMed
7. 7.↵
   1. Perrone A,
   2. Guerrisi P,
   3. Izzo L,
   4. et al

   . Diffusion-weighted MRI in cervical lymph nodes: differentiation between benign and malignant lesions. Eur J Radiol 2011;77:281–86

   CrossRefPubMed
8. 8.↵
   1. Herneth AM,
   2. Czerny C,
   3. Krestan C,
   4. et al

   . Role of diffusion weighted MRI in the characterization of lymph node metastases. In: Proceedings of the XVI International Congress of Head and Neck Radiology, Frankfurt/Main, Germany. September 4–6, 2003:C12
9. 9.↵
   1. Srinivasan A,
   2. Dvorak R,
   3. Perni K,
   4. et al

   . Differentiation of benign and malignant pathology in the head and neck using 3T apparent diffusion coefficient values: early experience. AJNR Am J Neuroradiol 2008;29:40–44

   Abstract/FREE Full Text
10. 10.↵
    1. Edge SE,
    2. Byrd DR,
    3. Compton CC,
    4. et al

    . AJCC Cancer Staging Manual. 7th ed. New York: Springer-Verlag; 2009
11. 11.↵
    1. van den Brekel MW,
    2. Castelijns JA,
    3. Snow GB

    . The size of lymph nodes in the neck on sonograms as a radiologic criterion for metastasis: how reliable is it? AJNR Am J Neuroradiol 1998;19:695–700

    Abstract
12. 12.↵
    1. King AD,
    2. Ahuja AT,
    3. Yeung DK,
    4. et al

    . Malignant cervical lymphadenopathy: diagnostic accuracy of diffusion-weighted MR imaging. Radiology 2007;245:806–13

    CrossRefPubMed
13. 13.↵
    1. Wang J,
    2. Takashima S,
    3. Takayama F,
    4. et al

    . Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging. Radiology 2001;220:621–30

    CrossRefPubMed
14. 14.↵
    1. Gray L,
    2. MacFall J

    . Overview of diffusion imaging. Magn Reson Imaging Clin N Am 1998;6:125–38

    PubMed
15. 15.↵
    1. Hudgins PA,
    2. Anzai Y,
    3. Morris MR,
    4. et al

    . Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. AJNR Am J Neuroradiol 2002;23:649–56

    Abstract/FREE Full Text
16. 16.↵
    1. Markkola AT,
    2. Aronen HJ,
    3. Paavonen T,
    4. et al

    . Spin lock and magnetization transfer imaging of head and neck tumors. Radiology 1996;200:369–75

    PubMed
17. 17.↵
    1. Maeda M,
    2. Kato H,
    3. Sakuma H,
    4. et al

    . Usefulness of the apparent diffusion coefficient in line scan diffusion-weighted imaging for distinguishing between squamous cell carcinomas and malignant lymphomas of the head and neck. AJNR Am J Neuroradiol 2005;26:1186–92

    Abstract/FREE Full Text
18. 18.↵
    1. Sumi M,
    2. Takagi Y,
    3. Uetani M,
    4. et al

    . Diffusion-weighted echoplanar MR imaging of the salivary glands. AJR Am J Roentgenol 2002;178:959–65

    PubMed
19. 19.↵
    1. Yoshino N,
    2. Yamada I,
    3. Ohbayashi N,
    4. et al

    . Salivary glands and lesions: evaluation of apparent diffusion coefficients with split-echo diffusion-weighted MR imaging–initial results. Radiology 2001;221:837–42

    PubMed
20. 20.↵
    1. Thoeny HC,
    2. Ross BD

    . Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 2010;32:2–16

    CrossRefPubMed
21. 21.↵
    1. Ng SH,
    2. Yen TC,
    3. Liao CT,
    4. et al

    . 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med 2005;46:1136–43

    Abstract/FREE Full Text
22. 22.↵
    1. Stuckensen T,
    2. Kovacs AF,
    3. Adams S,
    4. et al

    . Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg 2000;28:319–24

    CrossRefPubMed
23. 23.↵
    1. Crippa F,
    2. Leutner M,
    3. Belli F,
    4. et al

    . Which kinds of lymph node metastases can FDG-PET detect? A clinical study in melanoma. J Nucl Med 2000;41:1491–94

    Abstract/FREE Full Text
24. 24.↵
    1. Yamazaki Y,
    2. Saitoh M,
    3. Notani KI,
    4. et al

    . Assessment of cervical lymph node metastases using FDG-PET in patients with head and neck cancer. Ann Nucl Med 2008;22:177–84

    CrossRefPubMed